Challenges of New Target Pathways in NSCLC
Speaker: Martin Reck
- Which signalling pathways are key in NSCLC?
- Which axes are not targettable so far?
- In terms of oncogenic drivers, where do we stand in therapeutic targeting today?
- What are current drawbacks and possible future improvements in targeted therapies against lung cancer?
- In your opinion, where should research be directed in the future?